anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
With the aging population, the needs for total joint replacement are increasing. On the basis of 2000-to-2014 data from National Inpatient Sample (NIS), primary total knee arthroplasty (TKA) is projected to grow by 85% to 1.26 million procedures in the United States by 2030. In a 2012 report of Orthopaedic Industry, and the global sales of joint replacement products exceeded $49.3 billion, with knees taking about half of them. The high financial burden of joint replacement surgery on health care system highlights the importance of cost containment without compromising the quality of patient care.

Clinical pathways for total joint arthroplasty can reduce care variability and improve the quality of care. Taiwan's Bureau of National Health Insurance (BNHI) has initiated a prospective payment system for TKA under diagnosis-related group (DRG) since 1997. It was found the length of hospital stay, and the medical expenditure could be reduced because standard clinical pathways were implemented in most hospitals. However, to optimize the results and meet with patients' expectation are more challenging currently than before because the length of hospitalization is markedly reduced and the standard care processes are accelerated. The accelerated programs for total joint arthroplasty are revolutionizing the standard clinical pathways. Patients can even be discharged from the hospital within one day after the surgery. While a successful joint replacement surgery depends on well-practiced clinical pathways delivered in a timely manner, patient's medical literacy should also have a significant impact for his or her recovery. Unfortunately, patients may acquire incorrect information from the internet or have unrealistic expectations before or during the hospitalization that may compromise the decision making and clinical results.

Recently, the emerging technologies of the electronic medical record and medical informatics have made challenges to the traditional healthcare models such as the clinical pathways. The integration of informatics technology also provides an opportunity to modernize the clinical pathways. But the effect of an interactive infotainment system on TKA is unknown. The purpose of this study was to analyze whether the implementation of an interactive infotainment system into a standard clinical pathway of TKA could influence the hospital course and the medical quality in an arthroplasty specialty ward.
INTRODUCTION: The aim of this article is to summarize, compare, and assess possible association in individuals with or without rheumatoid arthritis (RA) for periodontitis.
EVIDENCE ACQUISITION: Three study repositories were searched for quantitative studies examining the relationship between periodontal disease and rheumatoid arthritis between 2000 and December 2022. Quality was evaluated using the Newcastle Ottawa Scale (NOS). The standardized mean difference (SMD), with a random effect model and a P value of 0.05 as the significance level, was utilized as a summary statistic measure.
EVIDENCE SYNTHESIS: Fourteen papers were included in the descriptive synthesis. Thirteen were qualified for meta-analysis. Our findings suggest a link between the two conditions in terms of clinical attachment levels (CAL), tooth loss, Plaque Index, and probing depth. The estimated SMD for CAL was found to be 0.68 (95% CI: 0.15-1.21) (P<0.01). For tooth loss, the forest plot analysis revealed an SMD of 1.62 (95% CI: 0.48-2.76) (P=0.005). Similarly, for pocket depth, the SMD was 0.53; CI: 0.07-0.99 (P>0.05). The pooled estimates for plaque index were 0.29; CI: 0.03-0.61 (P>0.05). The funnel plot showed a symmetric distribution with the absence of systematic heterogeneity.
CONCLUSIONS: Although our data suggest a link between periodontal disease and rheumatoid arthritis, larger population-based investigations are needed to validate this connection. Case-control studies must pave the way to more rigorous investigations with well-defined populations and clinical outcomes as primary outcome measures.
The excessive consumption of sugar-containing foods contributes to the development of a number of diseases, including obesity, diabetes mellitus, etc. As a substitute for sugar, people with diabetes mellitus and obesity most often use sweeteners. Sweet proteins, in particular brazzein, are an alternative to synthetic sweeteners that have natural origin, are broken down in the intestines along with food proteins, and do not affect blood sugar and insulin levels. The purpose of the review was to analyze the available data on the sweet protein brazzein, its physical and chemical properties, existing biotechnological methods of production, and prospects for application in the food industry in order to further develop an optimized heterologous expression system. Material and methods. Google Scholar, Scopus, Web of Science, PubMed, RSCI and eLibrary.ru databases were used for collecting and analyzing literature. Search depth - 30 years. Results. Numerous studies of the physical and chemical properties of brazzein have demonstrated its high potential for use in the food industry. In particular, a short amino acid sequence, thermal stability, the ability to maintain its structure and sweet properties in a wide pH range, hypoallergenicity, lack of genotoxicity, and an extremely high level of sweetness compared to sucrose allow us to conclude that its use is promising. Mutant variants of brazzein have been generated, the sweetest of which (with three amino acid substitutions H31R/E36D/E41A) exceeds sucrose sweetness by 22 500 times. To date, various systems for the expression of recombinant brazzein have already been developed, in which bacteria (Escherichia coli, Lactococcus lactis, Bacillus licheniformis), yeast (Komagataella phaffii, Kluyveromyces lactis, Saccharomyces cerevisiae), plants (Zea mays, Oryza sativa, Lactuca sativa, Nicotiana tabacum, Daucus carota) and animals (Mus musculus) have been used. Conclusion. Due to its high sweetness, organoleptic properties and long history of human consumption, brazzein can be considered as a promising natural sweetener. Despite the short peptide sequence, the production of the recombinant protein faced a number of problems, including low protein yield (for example, it could only be detected in mouse milk by Western blot hybridization) and loss of sweetness. Thus, further optimization of the process is necessary for widespread brazzein use in the food industry, which includes the selection of an adequate producer and the use of extracellular expression systems to reduce the final cost of the product.
The invention discloses an antioxidant peptide AOP-OM1 as well as a preparation method and an application thereof. The antioxidant peptide AOP-OM1 has amino acid sequences as shown in SEQ ID No. 1. The preparation method comprises the following steps of separating and purifying skin secretions of odorrana livida. A novel antioxidant is found in the skin of an amphibian odorrana livida, the chemical nature of the antioxidant is polypeptide, and the antioxidant, different from traditional two antioxidants, is encoded by a gene and but has very small molecular weight. The novel antioxidant peptide AOP-OM1, which is obtained from the skin of the odorrana livida growing in China, has very strong antioxidant activity, which is about 200 times of that of vitamin E.
PURPOSE: A pharmaceutical composition containing bisphosphonate, pH-sensitive polymers, foaming agent, and buffer is provided to prevent gellet simulation due to gastric reflux. CONSTITUTION: A pharmaceutical composition contains bisphosphonate, pH-sensitive polymers, foaming agent, and buffer. The pH-sensitive polymer forms gel under pH 3.5. The pH-sensitive polymers are alginic acid or metal salt thereof. The bisphosphonate is alendronate, risedronate, ibandronate acid, metal salt, anhydride, or hydrate thereof. The buffer is citric acid, and sodium citrate. The pharmaceutical composition is used in the form of solution, suspension, foaming pill, or foaming granule.
The present invention relates to a microwave auxiliary extraction method of licorice effective components. After liquoric roots are crushed and soaked, the combined technology of microwave irradiation processing and Soxhlet extraction is used in the extraction process of the liquoric roots. After the liquoric roots are soaked with water, microwave processing is carried out under normal pressure, microwave radiation power density is controlled from 30 to 70 W/g, microwave radiation time is from 10 to 30 seconds, and water temperature is below a boiling point. In the soaking process of the liquoric roots, the quantity of added water is 1.5 to 3.5 times of that of medicinal materials, soaking time is from 1 to 10 minutes, and extraction time is from 0.5 to 2.5 hours. The microwave auxiliary extraction method has the advantages that the characteristics of the microwave technology and the traditional Soxhlet extraction technology are integrated, leaching efficiency is obviously enhanced, and glycyrrhizic acid yield is increased; the problems of long extraction time and large solvent dosage of traditional technologies are overcome; and because water is used as an extraction agent, no organic solvent is residual, which has no pollution to environment. The microwave auxiliary extraction method has no special requirements for the existing microwave equipment, and has less change on the existing technologies. The microwave auxiliary extraction method of licorice effective components has simple and reliable process, and is suitable for industrial production.
To provide compositions for the treatment of meibomian gland dysfunction.SOLUTION: A composition comprises a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates. The composition is substantially free of surfactants and dispersing agents. The composition is suitable for topical administration on the eyelid margin. The selenium disulfide is dispersed in the anhydrous semi-solid ophthalmic base. The anhydrous semi-solid ophthalmic base is an oil-based base.SELECTED DRAWING: Figure 2
The objective of this study was to assess the clinical effectiveness and safety of type A botulinum toxin in the treatment of refractory overactive bladder in adolescents. We conducted a retrospective analysis of 37 adolescent patients with refractory overactive bladder who were treated at the Urology Department of Hangzhou Third People's Hospital between January 2018 and August 2023. These patients received intravesical injections of type A botulinum toxin at a concentration of 10 U/mL, with an average of 20 injection points. We recorded changes in urination diaries and urodynamic parameters both before and 1 month after treatment. After 1 month of treatment, significant improvements were observed in several parameters, when compared to the pretreatment values. These included daytime frequency of urination (11.13 ± 6.45), average single void volume (173.24 ± 36.48) mL, nighttime frequency of urination (2.43 ± 0.31), urgency episodes (3.12 ± 0.27), initial bladder capacity (149.82 ± 41.34) mL, and maximum bladder capacity (340.25 ± 57.12) mL (all P < .001). After the first treatment, 5 patients had mild hematuria, 4 patients had urinary tract infection, and 1 patient had urinary retention, which was relieved after catheterization. No serious complications or adverse reactions were observed in other patients. The follow-up period ranged from 6 to 18 months, and the duration of efficacy varied from 2 to 8 months. Eight patients who initially had treatment failure achieved symptom relief after reinjection. In adolescents with refractory overactive bladder who do not respond well to conventional drug therapy, type A botulinum toxin can be administered safely and effectively. It significantly improves lower urinary tract symptoms and enhances the quality of life for these patients.
The skin rejuvenation and healing mixture of peptide components significantly accelerates the healing of wounds. It is particularly useful for the treatment of chronic, fire and complex wounds, as well as for the treatment of general, post-operative or burn wounds. In healthy patients, the mixture reduces the time required for healing to a minimum of one third; in the case of difficult to heal wounds, the skin rejuvenation and healing mixture of peptide components reduces the time required for healing by a minimum of 7. For chronic wounds, in particular bedsores and venous ulcers, the skin renewal and healing mixture of the peptide components ensures an improved wound healing or even a complete healing of the wound due to the combined action of the peptide components. Preferably, the skin rejuvenating and healing mixture of peptide components is applied to the wound as a sterile protein and a glycogel matrix, preventing the development of infection, thus making the wound healing more effective. The skin rejuvenating and healing mixture of peptide components can be applied in cosmetic drugs and cosmetics.
This study was designed to simulate a real-world application of Exact Science's Multicancer Early Detection (MCED) test. Participants will be offered the Exact Science's MCED test annually for 3 years. If at any point during those 3 years a participant is diagnosed with cancer, they will become ineligible for further testing. Data will be collected for 5 years following the baseline test.

There will be two data collection approaches as part of this study. The first will be collection of self-report data related to the testing experience. The second will be periodic and largely automated extraction of pre-specified data elements from existing electronic data sources. A comparison data set will be constructed from records of individuals who did not receive the MCED test.
As this is a feasibility study, the main analysis will focus on within-group change over the intervention period of 3 months using indices of reliable change(36). This method assesses the number of people who changed in each of the groups based on the magnitude of change relative to pre-post variability and correlation. We will estimate the proportion of people with reliable change. Estimates from the pilot study will be used to plan the main trial if the pilot demonstrates feasibility. For the maintenance period, reliable change from baseline will also be estimated and used to identify the proportion of people who maintained reliable change or who gained/lost this status.

The study is designed to detect a minimal important within-group change of moderate magnitude or greater (effect size ½ standard deviation) with adequate precision. A sample size of 20 in the intervention with completed follow-up will provide a 95% confidence interval with precision that excludes an effect size of 0.03.
Pseudohypoparathyroidism (PHP) is a rare genetic disorder characterised by a non-functioning PTH. Usually, the diagnosis is made following (symptomatic) hypocalcaemia. We describe a case in which epileptic seizures and abnormalities in dental development were the main clinical manifestation of PHP type 1B. This case demonstrates the importance of screening for hypocalcaemia in patients with de novo epileptic seizures. In addition, antiepileptic medications themselves may interfere with calcium-phosphate metabolism, causing or aggravating a hypocalcaemia as well. By correcting the calcium level, a resolution of these symptoms could be obtained.
Standard blood culture process will be performed concurrently on select positive blood culture specimens during the study period. BCID2 will NOT be performed on these specimens.
Myelofibrosis (MF) is a pathological process characterized by dysplasia of bone marrow fibrous tissue, clonal proliferation of potential stem cells, inflammatory changes in the bone marrow microenvironment, and extramedullary hematopoiesis. Bone marrow histopathology is the gold standard for diagnosis, but because of the invasive nature of the puncture, repeated examination is not possible to dynamically monitor the disease process. In addition, due to the focal nature of puncture biopsy, it can not accurately reflect the systemic disease. 18F-FDG PET/CT provides visual assessment of MF, but its diagnostic effectiveness decreases as MF progresses. 18F-FAPI PET/MRI characterizes fiber activation processes in a variety of diseases. This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.
PROBLEM TO BE SOLVED: To diagnose curled hair including the extent of curl by permeating a hair with organic and/or inorganic salts, cutting the hair and observing the cross-section thereof, and then analyzing the unevenness of permeation rate in the plane for various substances. SOLUTION: A pair 1 is immersed into an aqueous solution of a compound exhibiting fluorescence or visible absorption or containing an element which is not contained 1% or more in the hair, e.g. an aqueous solution of fluorescence isothiocyanate (FITC). The hair is cleaned, dried and embedded and cut by means of microtomb and then the cut face is observed by a method for imaging the distribution of permeated compound using a vertical illumination fluorescent microscope, for example, in case of an FITC. The observation results, e.g. a photograph, are analyzed using an image analyzer and the like. If the ratio of distance A from the surface la to the fastest part of permeation front 1b penetrating the compound and the distance B to the slowest part is equal to 1, it represents a straight hair and if the ratio is higher than 1, it represents a curled hair.  Higher ratio of A/B represents higher extent of curl.
Plastic polymers were largely added with chemical substances to be utilized in the items and product manufacturing. The leachability of these substances is a matter of concern given the wide amount of plastic waste, particularly in terrestrial environments, where soil represents a sink for these novel contaminants and a possible pathway of human health risk. In this study, we integrated genetic, molecular, and behavioral approaches to comparatively evaluate toxicological effects of plastic leachates, virgin and oxodegradable polypropylene (PP) and polyethylene (PE), in Drosophila melanogaster, a novel in vivo model organism for environmental monitoring studies and (eco)toxicological research. The results of this study revealed that while conventional toxicological endpoints such as developmental times and longevity remain largely unaffected, exposure to plastic leachates induces chromosomal abnormalities and transposable element (TE) activation in neural tissues. The combined effects of DNA damage and TE mobilization contribute to genome instability and increase the likelihood of LOH events, thus potentiating tumor growth and metastatic behavior ofRasV12 clones. Collectively, these findings indicate that plastic leachates exert genotoxic effects in Drosophila thus highlighting potential risks associated with leachate-related plastic pollution and their implications for ecosystems and human health.
Group A (n=14) will receive Muscle Energy Technique (MET) combined with stationary Cycling. In the first three days, an initial assessment will be conducted, including Visual Gait Analysis, the Observational Gait Scale, and the Foot Posture Index. From Week 1 to 4, MET will involve the patient contracting for 5-10 seconds while the therapist resists, followed by a rapid 10-second stretch (3-5 repetitions), along with stationary Cycling for 5-10 minutes. A follow-up assessment will occur in Week 4. From Week 5 to 8, the same protocol will continue with 5-8 repetitions and cycling for 10-20 minutes, concluding with a final assessment in Week 8.
The present invention belongs to the field of nuclear medicine, and relates to a granzyme B targeting complex, a radiopharmaceutical, a preparation method therefor, and a use thereof. The structure of the granzyme B targeting complex is shown in formula (I), wherein R is any one among a bifunctional chelating group or derivative thereof for radionuclide labeling. The granzyme B targeting complex provided by the present invention can undergo radionuclide labeling to prepare a granzyme B targeting radiopharmaceutical. The provided granzyme B targeting radiopharmaceutical is simple to prepare. Compared with other granzyme B targeting drugs, the described complex has better pharmacokinetic properties and metabolic stability in vivo. The expression level of granzyme B in vivo can be monitored non-invasively by means of nuclear medicine imaging.
BACKGROUND: Controlled trials have consistently demonstrated the efficacy of poly(ADP-ribose) polymerase inhibitors (PARPis) in patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1 or BRCA2 alterations (BRCAalt). However, the reported efficacy of PARPi for alterations in other homologous recombination repair (HRR) genes is less consistent. We sought to evaluate the routine practice effectiveness of PARPi between and within these groups.
DESIGN: Patient-level data from a deidentified nationwide (USA-based) cancer clinico-genomic database between January 2011 and September 2023 were extracted. Patients with mCRPC and comprehensive genomic profiling by liquid biopsy [circulating tumor DNA (ctDNA)] or tissue (tumor) biopsy and who received single-agent PARPi were included and grouped by BRCAalt, ATMalt, other HRR, or no HRR. We further subcategorized BRCAalt into homozygous loss (BRCAloss) and all other deleterious BRCAalt (otherBRCAalt).
RESULTS: A total of 445 patients met inclusion criteria: 214 with tumor and 231 with ctDNA. BRCAalt had more favorable outcomes to PARPi compared with ATM, other HRR, and no HRR groups. Within the BRCAalt subgroup, compared with other BRCAalt, BRCAloss had a more favorable time to next treatment (median 9 versus 19.4 months, P = 0.005), time to treatment discontinuation (median 8 versus 14 months, P = 0.006), and routine practice overall survival (median 14.7 versus 19.4 months, P = 0.016). Tumor BRCAloss prevalence (3.1%) was similar to ctDNA prevalence in liquid biopsy specimens with high tumor fraction (>20%). BRCAloss was not detected in orthogonal germline testing.
CONCLUSIONS: PARPi routine practice effectiveness between groups mirrors prospective trials. Within the BRCAalt group, BRCAloss had the best outcomes. Unless the ctDNA tumor fraction is very high, somatic tissue testing (archival or metastatic) should be prioritized to identify patients who may benefit most from PARPi. When tissue testing is not clinically feasible, sufficient ctDNA tumor fraction levels for detection are enriched at clinical timepoints associated with tumor progression.
Participants randomized to the active waitlist-control group gains access to online mindfulness material for 12 weeks, however, using the material is non-mandatory. After completing the waitlist, participants are offered the i-TREAT intervention. The active waitlist was implemented to prevent potential adverse effects of being on a passive waitlist (which currently comes closest to treatment as usual since no other treatment modalities exist for the target group in the Danish psychiatry).
Patients receive crizotinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.